Bay Area Lifesciences Roundtable

Please join Sidley for the Bay Area Lifesciences Roundtable, an afternoon of provocative discussions addressing cutting-edge trends and hot topics.

AGENDA

1:00 p.m.
Registration

1:30 p.m.
Program

4:30 p.m.
Cocktail reception

WHO SHOULD ATTEND

Executives, Investors, General Counsel, and Company Counsel

CLE

CLE credit for this program is pending.

FEATURED PANELS

China & Beyond: Opportunities Across Asia
With prominent China-based companies in political cross-hairs and facing unpredictable geopolitics, our panel takes stock of how biomedical companies and investors remain engaged with China while mitigating risk, and seek regional opportunities in Japan, Korea, and Singapore.

SPEAKERS

• Judith Li, Partner, Lilly Asia Ventures
• Mark Noguchi, Advisor, Chugai Pharmaceutical Co.
• Andrew Wong, Vice President, Global Head, Bayer Co.Labs
• Tom Duley, Partner, Technology and Life Sciences Transactions, Sidley
• Josh Hofheimer, Partner, Technology and Life Sciences Transactions, Sidley

AI-Enabled Life Sciences Technologies: Exploring the Frontiers of Innovation and Boundaries of Responsibility
Artificial intelligence is being used to build models that predict the behavior of biological systems and mimic human responses to develop diagnostics and therapies. These models are used in a range of applications that could be significantly advantageous to, and disruptive of, the biopharma industry. During this panel we will discuss the current “state of the art” of such models, how they can be utilized to diagnose and treat disease, as well as current regulatory, implementation, and ethical challenges to be navigated.

SPEAKERS

• Colin Hill, Co-Founder and CEO, Aitia
• Josh Reicher, M.D., Co-Founder, IMVARIA Inc.
• Ryan Spiers, Associate General Counsel, Google Ventures
• Stephen Abreu, Partner, Technology and Life Sciences Transactions, Sidley
• Meena Datta, Partner, Healthcare, Sidley

Taking Stock of Paradigm-Shifting Developments from FDA
This panel will focus on two FDA developments with significant potential impact on product development and market dynamics across the life sciences industry:

• FDA efforts to advance approvals of cell and gene therapy products, including through accelerated approval
• New regulations for laboratory-developed tests that could significantly alter the business landscape for diagnostics, including for biopharma companies relying on companion and complementary tests to support product use

SPEAKERS

• Robin Cowie, Chief Financial Officer, Biodesix
• Jun Li, Regulatory Attorney at BioMarin Pharmaceutical Inc.; former FDA Regulatory Counsel
• Amar Murugan, Executive Vice President, Chief Legal Officer, Atara Biotherapeutics, Inc.
• Torrey Cope, Partner, Food, Drug and Medical Device, Sidley
• Emily Marden, Senior Counsel, Food, Drug and Medical Device, Sidley

For more information, contact globallifesci@sidley.com.